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Background: Concern exists that the prolonged application of immunomodulators to treat atopic dermatitis
may cause systemic immunosuppression.
Aims: In a 7-month, multicentre, randomised, controlled trial, we investigated the equivalence of response
to vaccination against meningococcal serogroup C disease with a protein-conjugate vaccine in children
(2–11 years) with moderate to severe atopic dermatitis, by applying either 0.03% tacrolimus ointment
(TAC-O; n = 21) or a hydrocortisone ointment regimen (HC-O; n = 111).
Methods: TAC-O was applied twice daily (bid) for 3 weeks, and thereafter daily until clearance.
1% hydrocortisone acetate (HA) for head/neck and 0.1% hydrocortisone butyrate ointment for trunk/limbs
was applied bid for 2 weeks; thereafter HA was applied bid to all affected areas. At week 1, patients were
vaccinated with protein-conjugate vaccine against meningococcal serogroup C, and challenged at month
6 with low dose meningococcal polysaccharide vaccine. The control group (44 non-atopic dermatatits
children) received the primary vaccination and challenge dose. Assessments were made at baseline,
weeks 1 and 5, and months 6 and 7. The primary end point was the percentage of patients with a serum
bactericidal antibody (SBA) titre >8 at the week 5 visit.
Results: The response rate (patients with SBA titre >8) was 97.5% (confidence interval (CI) approximately
97.3 to 100), 99.1% (94.8 to 100) and 97.7% (93.3 to 100) in the TAC-O, HC-O and control groups,
respectively.
Conclusions: The immune response to vaccination against meningococcal serogroup C in children with
atopic dermatitis applying either 0.03% TAC-O or HC is equivalent. Ointment application does not affect
the immediate response to vaccination, generation of immune memory or humoral and cell-mediated
immunity.
A
topic dermatitis is a chronic, pruritic, inflammatory
skin disease that can seriously affect the health and
quality of life of the patient. Intense itching is the
predominant symptom and excessive scratching can cause
damaging excoriations, erosions and lichenification of the
skin.1 The disease is most common during childhood, with
80–90% of children having onset before 5 years of age,2 and is
likely to persist into adulthood in those who are severely
affected.3 The exact pathogenesis of atopic dermatitis is
unknown, but it is recognised that T cell-mediated reactions4
and increased eosinophil levels5 are involved in the inflam-
matory response.
Atopic dermatitis usually has a relapsing course, and
requires long-term continuous or intermittent treatment.
Emollients provide symptomatic relief by reducing the
intense itching and inflammation. However, for the treat-
ment of acute exacerbations, most patients require topical
treatment with either corticosteroids or calcineurin inhibitors
such as tacrolimus or pimecrolimus. Children with moderate
to severe atopic dermatitis have large affected body surface
areas, often with open and weeping lesions, and this raises
concerns that the prolonged application of topical immuno-
modulators may cause systemic immunosuppression. Current
evidence is that the percutaneous absorption of tacrolimus
and pimecrolimus is minimal.6–9 Nonetheless, as atopic
dermatitis often occurs in young children who are under-
going childhood immunisation programmes, it is important
to determine whether topical immunomodulators have an
effect on the humoral and cell-mediated immune response to
vaccination.
Information about the immune response to vaccination of
patients with atopic dermatitis treated with topical immu-
nomodulators is scarce. Several studies, however, have
investigated the immune response to vaccination of children
with corticosteroid-dependent asthma. It seems that children
receiving short-term low to moderate daily maintenance
doses of systemic corticosteroids can receive live virus
vaccines without marked suppression of the antibody
response.10 Hanania et al11 found that children with asthma
receiving high-dose inhaled corticosteroids had a normal
response to A antigens of the inactivated influenza vaccine.
Other studies on children with asthma found no association
between inhaled corticosteroid use and varicella vaccine
failure,12 or an impaired immune response to pneumococcal
vaccines.13 With regard to children with atopic dermatitis
applying topical immunomodulators, Papp et al14 reported
that treating children with 1% pimecrolimus cream for up to
Abbreviations: SAE, serious adverse event; SBA, serum bactericidal
antibody; TAC-O, tacrolimus ointment
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2 years did not affect the seropositivity rates for tetanus,
diphtheria, measles or rubella after vaccination. In a small US
study of 23 children with atopic dermatitis, the application of
0.03% tacrolimus ointment (TAC-O) for 7 weeks had no
effect on the serological response to pneumococcal poly-
saccharide vaccine.15
To increase our knowledge of the immune response to
vaccination of children with atopic dermatitis treated with
topical immunomodulators, we investigated whether the
application of a hydrocortisone regimen or 0.03% TAC-O had
any effect on the immune response after vaccination against
meningococcal serogroup C disease.
METHODS
Study design
This was a 7-month, randomised, double-blind, comparator-
controlled, clinical trial conducted in 27 centres in seven
European countries and 10 centres in Australia. The study
was conducted in accordance with the ethical principles
described in the Declaration of Helsinki, and the ethics
committee of each centre reviewed the protocol and granted
approval before the study began. Assessments were con-
ducted at baseline (day 1, treatment allocation) and at weeks
1 and 5, and months 6 and 7.
Patients
After receiving written informed consent from the patient’s
legal representative or the patient, children aged 2–11 years
diagnosed with atopic dermatitis on the basis of the criteria
of Hanifin and Rajka16 were enrolled in the study. The
patients were required to have a grading of moderate to
severe atopic dermatitis (ie, score at least 4.5) as defined by
the scoring system of Rajka and Langeland.17
Children aged 2–11 years who did not have atopic
dermatitis were enrolled to form the control group.
For the two groups of patients with atopic dermatitis,
randomisation was 1:1, stratified by centre and generated by
the study sponsor. The sponsor’s clinical trial packaging
department prepared blinded treatment boxes and tubes that
could be identified only by patient number. Labels detailing
lot numbers and expiry date were identical for all ointment
tubes. The investigator reviewed the patient’s diary card at
weeks 1 and 5 to assess compliance with the study treatment.
Treatment
Patients with atopic dermatitis applied 0.03% TAC-O twice
daily for 3 weeks (morning and evening). Thereafter, TAC-O
was applied once daily until clearance (ie, absence of
itching); vehicle ointment formed the second daily applica-
tion so as to maintain blinding. Patients in the hydrocorti-
sone group applied 1% hydrocortisone acetate ointment to
the head and neck, and 0.1% hydrocortisone butyrate
ointment to the trunk and limbs twice daily for 2 weeks.
Thereafter, 1% hydrocortisone acetate was applied twice daily
to all affected body areas until clearance.
Treatments prohibited during the study included other
topical corticosteroids for the treatment of atopic dermatitis,
systemic corticosteroids, ultraviolet light treatment (UVA,
UVB), systemic non-steroidal immunosuppressants and
other topical immunomodulators (eg, pimecrolimus). The
washout phase for these treatments was 4 weeks for UVA
and UVB, 2 weeks for systemic non-steroidal immunosup-
pressants, 5 days for systemic corticosteroids and 3 days for
topical corticosteroids and immunomodulators.
None of the controls had atopic dermatitis, and therefore
these children received no treatment with ointment.
Patients with atopic dermatitis and controls were vacci-
nated with a protein-conjugate vaccine against meningococ-
cal serogroup C at week 1 (Meningitec, Wyeth
Pharmaceutica, Hants, UK), and challenged with a low dose
of meningopolysaccharide vaccine at month 6 (AC VAX,
SmithKline Beecham Biologicals, Rixensart, Belgium).
Assessments
Meningococcal C conjugate vaccines produce high levels of
serogroup C-specific immunoglobulin (Ig)G antibodies and
serum bactericidal antibody (SBA) activity that provide
immune protection against serogroup C meningococcal
disease.18 19 The primary end point of this study was the
percentage of patients who at the week 5 visit had an SBA
titre >8, which is an accepted correlate of protection.20
The change in serogroup C-specific IgG avidity over time is
a useful marker of priming for immunological memory
Table 1 Demographics and baseline characteristics of the per-protocol population
HC regimen (n = 111) 0.03% TAC-O (n = 121) Control (n = 44)
Age (years)
Mean (SD) 6.0 (3.1) 6.2 (3.1) 7.3 (2.3)
Min–max 2–11 2–11 2–11
Sex, n (%)
Male 47 (42.3) 58 (47.9) 27 (61.4)
Female 64 (57.7) 63 (52.1) 17 (38.6)
Ethnic group
White 106 (95.5) 116 (95.9) 44 (100.0)
Black 1 (0.9) 0 (0.0) 0 (0.0)
Oriental 2 (1.8) 2 (1.7) 0 (0.0)
Other 2 (1.8) 3 (2.5) 0 (0.0)
Severity of AD on day 1, n (%)
Moderate (4.5–7.5) 64 (57.7) 77 (63.6) NA
Severe (8–9) 47 (42.3) 44 (36.4) NA
Total affected body surface area (%),
day 1—median (min–max)
32.0 (2–100) 27.0 (1–100) NA
AD, atopic dermatitis; HC, hydrocortisone; max, maximum; min, minimum; NA, not applicable. TAC-O, tacrolimus
ointment
Table 2 Day of last ointment application for the per-
protocol population







HC, hydrocortisone; max, maximum; min, minimum; TAC-O, tacrolimus
ointment.
906 Hofman, Cranswick, Kuna, et al
www.archdischild.com
 on 28 August 2008 adc.bmj.comDownloaded from 
because it indicates a T cell-dependent antibody response.21 22
Therefore, a secondary end point of the study was the
measurement of serogroup C-specific IgG antibody avidity.
Additional secondary end points included measurement of Ig
levels (meningococcal serogroup C-specific IgG, total IgG and
IgG subclasses, IgM, IgA, IgE) and lymphocyte subsets (CD3,
CD4, CD8, CD19).
Assays for SBA, meningococcal serogroup C-specific IgG
and antibody avidity were carried out as previously
described.21
Clinical efficacy was measured by the physician’s global
evaluation of clinical response and assessments of affected
body surface area. Safety was assessed by the monitoring of
adverse events reported by the parent or observed by the
investigator. An adverse event was defined as any untoward
occurrence in a patient during the study, regardless of
whether it was related to the study treatment.
Statistical analyses
Sample size was calculated according to the published
method for clinical trials.23 It was assumed that with a
response rate of 75% in the hydrocortisone and TAC-O
groups, a d of 20% and a significance level of 5%, a sample
size of 100 patients per treatment group would be needed to
show equivalence with a power of 90%. To account for
protocol violations and possible early withdrawals from the
study, 125 patients were randomised to each treatment
group.
The full analysis population comprised all patients who
received at least one application of study ointment and were
vaccinated against meningococcal serogroup C. This popula-
tion was used for the clinical efficacy assessments. For the
analysis of the primary end point and all other immunolo-
gical parameters, the per-protocol population was used—that
is, all randomised patients who were compliant with the
study protocol before the primary end point assessment. The
safety population included all patients who received at least
one application of study ointment.
The primary end point was analysed by calculating two-
sided 95% confidence intervals (CIs) using the Newcombe
Wilson Score Method.24 Fisher’s exact test was used to
compare the incidence of adverse events between the two
groups of patients with atopic dermatitis.
RESULTS
As the per-protocol population was the primary analysis set
for the immunological parameters, only data related to these
patients are described unless otherwise stated. In total, 232
patients formed the per-protocol population (111 patients in
the TAC-O group and 121 patients in the hydrocortisone
group) and 44 patients formed the control group. The patient
groups were comparable with respect to demographic and
baseline characteristics (table 1).
More patients in the hydrocortisone group discontinued
the study prematurely (n = 20; 18.0%) compared with those
in the TAC-O group (n = 13; 10.7%) and the control group
(n = 2; 4.5%). Lack of efficacy was the main reason for
discontinuation in the hydrocortisone group (n = 8; 7.2%).
The main reasons for discontinuation in the TAC-O group
were lack of efficacy (n = 3; 2.5%) and ineffectiveness of
vaccination (n = 3; 2.5%). In the control group, one child
(2.3%) discontinued the study because the vaccination was
not effective, and another child discontinued because there
was no challenge dose at month 6. Duration of the study was
comparable among treatment groups. Patients in the hydro-
cortisone, TAC-O and control groups remained in the study
for a median of 213, 215 and 216 days, respectively.
Ointment usage
Adherence to treatment was good: 100% adherence in the
hydrocortisone group and 99.2% in the TAC-O group at week
5. Median (minimum–maximum) total ointment usage in
the hydrocortisone group between day 1 and week 5 was 86 g
(5–308 g) hydrocortisone acetate and 42 g (0–76 g) hydro-
cortisone butyrate. In the tacrolimus group, 79 g (0–366 g)
TAC-O and 19 g (0–150 g) vehicle ointment were applied
during the same period. Most patients applied ointment
either continuously or intermittently throughout most of the
study period (an average of 166 days in the hydrocortisone
group and 185 days in the tacrolimus group; table 2).
SBA titre
Both groups of patients with atopic dermatitis had a high
response rate at week 5, and there was no difference between
groups in the percentage of patients with an SBA titre >8
(table 3). Equivalence was observed: the two-sided 95% CI
for the difference between the two treatment groups with
atopic dermatitis (tacrolimus2hydrocortisone) was (26.2 to
2.8), which was within the prespecified equivalence margin
of (220 to 20). The response rate of the children in the
control group was similar to that of the children with atopic
dermatitis.
At month 6, the number (percentage) of patients with an
SBA titre >8 was 77 (93.9%), 88 (92.6%) and 36 (97.3%) for
the hydrocortisone, TAC-O and control groups, respectively.
The respective values, post-challenge, at month 7 were 88
(100%), 101 (99.0%) and 36 (100%).
Table 3 Patients (n (%)) in the per-protocol population










110 (99.1) 118 (97.5) 43 (97.7)
95% CI,
approximation
97.3 to 100 94.8 to 100 93.3 to 100
95% CI, Wilson
score
95.1 to 99.8 93.0 to 99.2 88.2 to 99.6
HC, hydrocortisone; TAC-O, tacrolimus ointment.
Difference in response rate (TAC-O–HC ointment group) at week
5 =21.6; 95% CI, approximation =24.9 to 1.7; 95% CI Newcombe–
Wilson =26.2 to 2.8.
Table 4 Meningococcal serogroup C-specific immunoglobulin G data (geometric mean)
for the per-protocol population
HC regimen (95% CI)
(n = 111)




Day 1 111 0.16 (0.13 to 0.20) 120 0.19 (0.15 to 0.24) 44 0.13 (0.10 to 0.17)
Week 5 111 16.2 (12.8 to 20.4) 121 12.5 (10.0 to 15.6) 44 15.0 (11.3 to 20.1)
Month 6 83 2.7 (2.0 to 3.7) 96 2.9 (2.2 to 3.8) 38 2.5 (1.8 to 3.3)
Month 7 89 9.7 (7.4 to 12.7) 104 9.7 (7.8 to 12.1) 38 7.2 (5.6 to 9.3)
HC, hydrocortisone; TAC-O, tacrolimus ointment.
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Geometric means for SBA titre were high at week 5,
decreased by month 6 and increased again at month 7 in all
the three groups (fig 1). There was no difference between the
two groups of patients with atopic dermatitis at any point
during the study, or between the patients with atopic
dermatitis and the children in the control group.
Other immunological parameters
Ig levels for meningococcal serogroup C-specific IgG imme-
diately increased after primary vaccination, decreased with
time and increased again after challenge with the low-dose
meningococcal polysaccharide vaccine (table 4).
Figure 2 shows that the antibody avidity indices increased
during the study in all three groups of children between week
5 and month 6, and again between months 6 and 7; this is
evidence of a T cell-dependent antibody response after
vaccination. We found no differences among the groups at
any time point.
Analysis of the IgG data over time showed that median
levels of total IgG and median IgG subclasses were similar for
all three groups and within the normal reference ranges. In
addition, median levels of IgA and IgM were comparable for
all three groups, and within the normal reference ranges.
Only IgE levels, as would be expected, were higher in patients
with atopic dermatitis than those in the control group.
Median levels of the absolute counts of the various
lymphocytes did not differ among groups, were stable over
time and were within the normal reference ranges.
Clinical improvement
Patients with atopic dermatitis in both treatment groups
experienced substantial clinical improvement during the
study. With respect to the physician’s global evaluation of
clinical response, by week 5, more patients in the TAC-O
group experienced clearance or excellent improvement
compared with the patients applying the hydrocortisone
regimen (41.1% v 29.8%). The median percentage of affected
total body surface area at week 5 was 11.5% in the TAC-O
group and 5.6% in the hydrocortisone group (p = 0.007,
Wilcoxon rank sum test).
Adverse events
The safety population comprised 124 patients in the hydro-
cortisone group and 133 and 50 patients in the TAC-O and
control groups, respectively. Altogether 97 (78.2%) patients,
100 (75.2%) patients and 32 (64.0%) patients in the
hydrocortisone, TAC-O and control groups reported adverse
events during the study. Patients applying TAC-O had
considerably more skin burning assessed by the investigator
to be causally related to treatment compared with those in
the hydrocortisone group (p = 0.036; table 5). Patients
applying hydrocortisone experienced significantly more
causally related aggravated atopic dermatitis (p = 0.03). In
both groups of patients with atopic dermatitis, most of the
causally related adverse events occurred at the site of
ointment application.
A few serious adverse events (SAEs) were reported during
the study, and the incidence and nature of the SAEs were
similar in the hydrocortisone and TAC-O treatment groups.
Table 5 Incidence of the most common* adverse events assessed to be causally related
to the study drug for the safety population
Primary system organ class preferred term
HC regimen
(n = 124), n (%)
0.03% TAC-O
(n = 133), n (%) p Value`
General disorders and administration site conditions
Application site burning 2 (1.6) 10 (7.5) 0.036
Application site erythema 3 (2.4) 2 (1.5) 0.675
Application site pruritus 4 (3.2) 8 (6.0) 0.380
Application site rash 0 (0.0) 3 (2.3) 0.499
Pain NOS 0 (0.0) 2 (1.5)
Infections and infestations
Application site infection 2 (1.6) 0 (0.0) 0.232
Eczema infected 2 (1.6) 2 (1.5) 1.000
Skin and subcutaneous tissue disorders
Dermatitis atopic aggravated 14 (11.3) 5 (3.8) 0.030
Pruritus 3 (2.4) 2 (1.5) 0.675
Rash NOS 4 (3.2) 1 (0.8) 0.200
HC, hydrocortisone; NOS: not otherwise specified (MedDRA term); TAC-O, tacrolimus ointment.
*At least 1% of patients; Causally related to study drug is defined as highly probable, probable, possible or not




























Figure 1 Serum bactericidal antibody (SBA) titre: geometric means and


































Figure 2 Antibody avidity: geometric means and two-sided 95%
confidence intervals.
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One case of herpes simplex and one case of asthma were
assessed as being ‘‘possibly’’ related to TAC-O. In both
patients, the SAE resolved after discontinuation of treatment.
No causally related SAEs were reported in the hydrocortisone
group.
The most common adverse event observed in the control
group of children was nasopharyngitis (n = 8, 16.0%),
followed by joint pain (n = 3, 6.0%) and otitis media (n = 3,
6.0%). The incidence rate of nasopharyngitis was similar to
that seen in the patients with atopic dermatitis.
We found no clinically relevant changes in laboratory
values or vital signs throughout the study in any of the
patients, and no differences between treatment groups.
DISCUSSION
As there is concern that the prolonged application of topical
immunomodulators to patients with atopic dermatitis may
cause systemic immunosuppression, the aim of this study
was to investigate whether these treatments affect the cell-
mediated response to vaccination. These study data clearly
showed that the application of either 0.03% TAC-O or
hydrocortisone ointment to children with moderate to severe
atopic dermatitis did not interfere with the ability of the child
to raise protective antibody levels after vaccination against
meningococcal serogroup C with a protein-conjugate vaccine.
The percentage of patients with atopic dermatitis who had an
SBA titre >8 at week 5 after primary vaccination was similar
to that of the children without atopic dermatitis.
Furthermore, the increases in SBA titre, meningococcal
serogroup C-specific IgG and antibody avidity indices
between months 6 and 7 provide evidence of the induction
of immune memory. As hydrocortisone butyrate is a more
potent topical immunosuppressant than 0.03% TAC-O, the
indication that even applying a mid-potent corticosteroid
twice daily to the trunk and limbs of children for 2 weeks did
not affect the immune response to vaccination is reassuring.
The immune response after vaccination against other
childhood diseases would probably be similar to that seen
in the children in this study who were vaccinated against
meningococcal serogroup C. In previous studies on vaccina-
tion of children with atopic dermatitis, the seropositivity
rates for tetanus, diphtheria, measles or rubella after
vaccination were unaffected even after 2 years of treatment
with 1% pimecrolimus cream,14 and in the US study the
serological response to pneumococcal polysaccharide vaccine
was unaffected by 7 weeks of treatment with 0.03% TAC-O.15
The safety profiles of 0.03% TAC-O and the hydrocortisone
regimen observed in this study were consistent with those
reported previously,25 26 and gave no reason for concern.
In conclusion, this study shows that after vaccination
against meningococcal serogroup C with a protein-conjugate
vaccine, there was no difference in immune response
between children with atopic dermatitis applying either
0.03% TAC-O or a hydrocortisone ointment and children
with no atopic dermatitis. The application of ointments
containing immunomodulators does not adversely affect the
immediate response to vaccination, the generation of
immune memory, or humoral and cell-mediated immunity
in childhood.
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school and residential opportunities for pain
management, as well as the chapter on
providing pain services in developing countries
where these are often unavailable owing to
more pressing public health concerns. Also, the
consistent emphasis placed on non-pharmaco-
logical approaches to pain relief (such as
cognitive–behavioural or physical treatments)
throughout several chapters points out the
essential role that these methods have as
complements to our conventional analgesic
pharmacopoeia.
This book is not intended as a comprehen-
sive volume on pain management in children,
and lacks the practicality of a potential
reference text in this field. However, it should
appeal to those practitioners who already have
a strong interest in pain management and are
seeking state-of-the-art information on what is
currently being done and explored by experts
in their field, and to those who are willing to
implement new and creative ways of ‘‘bringing
pain relief to children’’.
C J Newman
Textbook of pediatric HIV care
Edited by Steven Zeichner, Jennifer Read.
Published by Cambridge University Press,
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dren and families
infected with and




study, but may be less valuable in managing
HIV positive children.
The book aims to provide ‘‘accessible infor-
mation’’ and hopes to become the ‘‘standard
reference for clinicians throughout the world’’.
However, the book mostly focuses on practice
in the US (not surprising when all but one of
the authors work there).
The book provides some useful background
information on HIV and its specific complica-
tions. It is well laid out, with many subhead-
ings, and every chapter has an aim at the start.
The chapters on virology and post-exposure
prophylaxis are useful.
The increasing number of drugs available for
children with HIV will make any textbook out
of date almost as soon as it is published. This is
probably the case here. To try to get round this,
links to web-based guidelines are given.
However, even the current Paediatric
European Network for Treatment of AIDS
(PENTA) guidelines (www.ctu.mrc.ac.uk/
penta/) are being revised to try to keep up
with this rapidly developing area.
The section on drug interactions provides a
useful list but does not reference the excellent
website from the University of Liverpool
(http://www.hiv-druginteractions.org/index.
asp).
Improvements needed in a second edition
include reference to the landmark HIV
Paediatric Prognostic Markers Collaborative
Study,1 recognition that the organism that
causes Pneumocystis carinii pneumonia is now
named P jiroveci (not P carinii), and contribu-
tions from some authors from outside the USA.
This book should be available in paediatric
departments that see children with HIV.
However, it would be more important for these
units to have access to the guidelines on the
CHIVA website (www.bhiva.org/chiva) and to
have access to expert advice. The recent
establishment of a national network for
paediatric HIV should make expertise about




1 HIV Paediatric Prognostic Markers Collaborative
Study Group. Short-term risk of disease progression
in HIV-1-infected children receiving no antiretroviral




T Hofman, N Cranswick, P Kuna, et al.
Tacrolimus ointment does not affect the
immediate response to vaccination, the gen-
eration of immune memory, or humoral and
cell-mediated immunity in children. Arch Dis
Child 2006;91:905–10. A typographical error
was introduced into the Aims section of the
Abstract of this paper. (TAC-O; n = 21)
should read (TAC-O; n = 121). In addition,
the second sentence of the results section of
the paper should read: In total, 232 patients
formed the per-protocol population (121
patients in the TAC-O group and 111 patients
in the hydrocortisone group) and 44 patients
formed the control group.
doi: 10.1136/adc.2006.0103093corr1
Inwald D P, Yen Ho S, Shepherd M N, et al. Arch
Dis Child 2006;91:928.
The name of the third author of this article
was spelt incorrectly—the correct spelling is M
N Sheppard.
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